SYDNEY EGAN: Open Payments
NPI 1396203758 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,195 in 108 payments from 15 companies in 2025. Trend: 2023 $3,195 · 2024 $2,482 · 2025 $2,195
Food & beverage: $2,195
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 10 | $346 |
| Otsuka America Pharmaceutical, Inc. | 17 | $300 |
| Alkermes, Inc. | 9 | $232 |
| Neurocrine BioSciences, Inc. | 13 | $230 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $219 |
| Teva Pharmaceuticals USA, Inc. | 11 | $217 |
| Supernus Pharmaceuticals, Inc. | 14 | $167 |
| Vanda Pharmaceuticals Inc. | 4 | $106 |
| ABBVIE INC. | 5 | $91 |
| Janssen Pharmaceuticals, Inc | 3 | $84 |
Products named: COBENFY, REXULTI, ARISTADA, INGREZZA, CAPLYTA, Qelbree, AUSTEDO XR, FANAPT.
Industry payments across NV — which companies pay providers there.
